Evidence map›Paper›PMID 40709914›Full record

ArticleJournal of medicinal chemistry2025

High-Affinity Probes for Androgen Receptor Imaging: From Cells and

Saheed A Ayodeji, Yaroslav Balytskyi, Destina Unaegbu, Allison Ingman, Christopher V Kelly, Sheryl Roberts

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saheed A AyodejiMolecular Therapeutics Program, Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, United States.ORCID 0000-0003-2876-8110
Yaroslav BalytskyiDepartment of Physics and Astronomy, College of Liberal Arts and Sciences, Wayne State University, Detroit, Michigan 48202, United States.
Destina UnaegbuMolecular Therapeutics Program, Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, United States.
Allison IngmanMolecular Therapeutics Program, Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, United States.
Christopher V KellyDepartment of Physics and Astronomy, College of Liberal Arts and Sciences, Wayne State University, Detroit, Michigan 48202, United States.ORCID 0000-0003-0886-8691
Sheryl RobertsMolecular Therapeutics Program, Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, United States.ORCID 0000-0002-2326-9120

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Analysis of Lipolytic Trafficking in Adipocytes.R01DK076629 · NIDDK · WAYNE STATE UNIVERSITY · PI James G Granneman, Christopher V Kelly · 2009 to 2026
$7.1M
NCI NIH HHS P30 CA022453NIDDK NIH HHS R01 DK076629
6 · The paper itself

Abstract

Castrate-resistant prostate cancer (CRPC) is driven by androgen receptor (AR) signaling. Imaging tools to monitor AR signaling dynamics are a high-priority goal. Here, we introduce ARi-FL, a series of visible- and near-infrared fluorescent AR inhibitors. Based on an aryloxy cyclohexane scaffold, a neolinker enabled amine-based conjugation to fluorophores. ARi-FL showed potent AR inhibition (IC

Indexed as

Androgen Receptor AntagonistsFluorescent DyesReceptors, AndrogenAnimalsCell Line, TumorComputer SimulationHumansMaleMiceStructure-Activity RelationshipAndrogen Receptor AntagonistsAR protein, humanFluorescent DyesReceptors, Androgen

Identifiers

PMID40709914
PMCPMC12362607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.